Subscribe
teva-english-logo-gray-web-5-1
Photo: Courtesy of Teva
3 August 2016Americas

Teva completes acquisition of Allergan generics business

Teva’s acquisition of Allergan’s generic business (Actavis Generics) has been completed, the company revealed yesterday.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Teva’s Allergan acquisition approved by FTC
28 July 2016   Teva announced yesterday that the Federal Trade Commission has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.


Editor's picks

Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025

Editor's picks

Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
Trump nixes Biden’s Executive Order on drug pricing
21 January 2025
Europe
EPO report reveals leading tech investors in Europe
16 January 2025
Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
EOFlow ordered to pay rival $452m over insulin patch trade secrets
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024

More on this story

Americas
Teva’s Allergan acquisition approved by FTC
28 July 2016   Teva announced yesterday that the Federal Trade Commission has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.

More on this story

Americas
Teva’s Allergan acquisition approved by FTC
28 July 2016   Teva announced yesterday that the Federal Trade Commission has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.

More features

UK court upholds EU SPC precedent, rejecting MSD’s appeal
Fish & Richardson doubles down in Chicago with new office
GSK seeks damages hike in ‘skinny label’ case
UPC orders Sanofi to fix ‘deficiencies’ in prostate cancer drug case
Dutch court axes Biogen’s MS patent, clearing way for generics
Munck Wilson Mandala brings in first-chair patent litigator from McGuireWoods
Goodwin hires ‘impressive’ partner for NY office
Fed Circ grants Teva temporary pause in Orange Book feud